Sep 8, 2025 07:14AM
Sep 5, 2025 11:03AM
Sep 5, 2025 07:05AM
Sep 5, 2025 07:05AM
May 19, 2025 04:05PM
May 19, 2025 04:05PM
Sep 17, 2024 07:07AM Regenxbio (RGNX) Appoints Mitchell Chan as CFO
Sep 17, 2024 07:05AM
Feb 27, 2024 04:05PM
Feb 7, 2024 11:40AM
Feb 7, 2024 11:40AM
Aug 30, 2023 07:06AM
Aug 30, 2023 07:05AM
May 23, 2023 07:10AM Regenxbio (RGNX) Receives FDA Regenerative Medicine Advanced Therapy Designation for RGX-121 Gene Therapy for Hunter Syndrome
May 23, 2023 07:05AM
May 3, 2023 04:05PM
Feb 28, 2023 04:05PM
Feb 24, 2023 09:21AM
Feb 24, 2023 09:20AM
Feb 22, 2023 03:00PM
Feb 22, 2023 03:00PM Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM
Aug 3, 2022 07:11AM
Aug 3, 2022 07:05AM
May 4, 2022 04:05PM
Mar 1, 2022 04:05PM
Feb 9, 2022 11:36AM
Feb 9, 2022 11:36AM
Feb 9, 2022 11:20AM Regenxbio (RGNX) Reports Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II
Feb 9, 2022 11:12AM
Sep 13, 2021 07:26AM
Sep 13, 2021 06:30AM
Sep 7, 2021 07:13AM
Sep 7, 2021 07:05AM
Aug 9, 2021 04:05PM
May 14, 2021 07:06AM Regenxbio (RGNX) Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for Treatment of MPS II at ASGCT
May 14, 2021 07:05AM
Mar 1, 2021 04:05PM
Feb 8, 2021 02:29PM
Feb 8, 2021 02:29PM
Dec 9, 2020 07:05AM
Dec 9, 2020 07:05AM
Jul 8, 2020 07:07AM Regenxbio (RGNX) Provides Update on Progress of Clinical Programs for Rare Genetic Neurodegenerative Diseases
Jul 8, 2020 07:05AM
Feb 25, 2019 09:25AM
Jan 3, 2019 04:05PM
Aug 8, 2018 07:30AM
Jul 23, 2018 09:31AM
Jun 13, 2018 07:02AM
Jun 11, 2018 04:08PM Regenxbio (RGNX) Announced $100M Accelerated License Payment from Novartis
Jun 11, 2018 04:05PM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All